In Brief: Nizoral AD
This article was originally published in The Tan Sheet
Executive Summary
Nizoral AD: Three years of Waxman/Hatch market exclusivity for Johnson & Johnson's ketoconozole 1% antidandruff shampoo granted until Oct. 10, 2000, according to a recent update to FDA's Orange Book. The exclusivity award is based on the clinical trials submitted in the NDA considered by the agency to be essential to the approval, according to FDA documents. The approval of the switch product involved a concurrent change to the indication of the company's prescription ketoconazole (2%) shampoo ("The Tan Sheet" Oct. 20, 1997, p. 3). J&J Consumer Products has not announced marketing plans for Nizoral AD...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning